Date:2/12/2013

p>® and the OTC conversion of Allegra^® on the company's receipt of significant royalties under the Allegra^® license agreement; the success of the sales of other products for which the Company receives royalties; the over-the-counter sale of Claritin, and competitive alternatives, including generic products for the treatment of allergies and the risk of new product introductions for the treatment of allergies including generic forms of Allegra^®; the risk that the company will not be able to replicate either in the short or long term the revenue stream that has been derived from the royalties payable under the Allegra^® license agreements; the success of the company's collaborations with customers including the collaboration with Bristol-Myers Squibb Company related to biogenic amine reuptake inhibitors; the risk that clients may terminate or reduce demand under any strategic or multi-year deal; the company's ability to enforce its intellectual property and technology rights; the company's ability to obtain financing sufficient to meet its business needs and to meet the covenants set forth in its agreements or to negotiate a waiver or amendment with its lenders; the company's ability to successfully partner or out-license novel compounds and lead candidates in its collaborative arrangements; the company's ability to successfully comply with heightened FDA scrutiny on aseptic fill/finish operations; the company's ability to integrate the acquisitions closed during 2010 and make such acquisitions accretive to the company's business model, the company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company's strategic investments and acquisitions to perform as expected, as well as those risks discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Co
'/>"/>

SOURCE AMRI Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. Quantum Materials Corporation Announces Non-Heavy Metal (Cadmium-Free) Tetrapod Quantum Dots
2. The In View Series Announces Plans for a New Series on 3D-Printing
3. Elsevier Announces the Launch of a New Journal: Journal of Forensic Radiology and Imaging
4. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
5. Murray Test Prep Announces the Launch of their Online Tutoring Services
6. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
7. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
8. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
9. DNA Genotek Inc. Announces $10,000 GenoFIND™ Genomic Services Award
10. Spectrum Announces bioWorld Distribution Agreement
11. Life Technologies Announces Fourth Quarter and Fiscal 2012 Results